Swedencare AB (publ) has completed the Canadian acquisition which was made public on July 24th, 2024, and carries out an issue of shares to the sellers
Kurs
-2,72%
Likviditet
7,09 MSEK
Prenumeration
Kalender
| Tid* | ||
| 2025-10-22 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-07-23 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-04-24 | N/A | Årsstämma |
| 2025-04-24 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | 07:30 | Bokslutskommuniké 2024 |
| 2024-10-23 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-26 | - | X-dag ordinarie utdelning SECARE 0.23 SEK |
| 2024-04-25 | - | Årsstämma |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-10-25 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-27 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-02 | - | X-dag ordinarie utdelning SECARE 0.22 SEK |
| 2023-04-28 | - | Årsstämma |
| 2023-04-28 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-10-19 | - | Extra Bolagsstämma 2022 |
| 2022-07-28 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-29 | - | X-dag ordinarie utdelning SECARE 0.20 SEK |
| 2022-04-28 | - | Årsstämma |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-24 | - | Split SECARE 1:5 |
| 2021-04-30 | - | X-dag ordinarie utdelning SECARE 0.80 SEK |
| 2021-04-29 | - | Årsstämma |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-10-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-11 | - | Extra Bolagsstämma 2020 |
| 2020-07-24 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-22 | - | X-dag ordinarie utdelning SECARE 0.70 SEK |
| 2020-04-21 | - | Årsstämma |
| 2020-04-21 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-26 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | X-dag ordinarie utdelning SECARE 0.00 SEK |
| 2019-04-25 | - | Årsstämma |
| 2019-04-25 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-10-25 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-04-26 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-25 | - | X-dag ordinarie utdelning SECARE 0.00 SEK |
| 2018-04-24 | - | Årsstämma |
| 2018-02-22 | - | Bokslutskommuniké 2017 |
| 2017-10-26 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-28 | - | X-dag ordinarie utdelning SECARE 0.00 SEK |
| 2017-04-27 | - | Årsstämma |
| 2017-04-27 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-10-27 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Swedencare AB (publ) has today gained access to the business of MedVant Inc. (“MedVant”), which was acquired on July 24th, 2024. MedVant has been distributing Swedencare subsidiary, RX Vitamins' product line exclusively in Canada since 2020. Through this strategic acquisition, Swedencare now enters the expansive Canadian vet market and receives a comprehensive product portfolio of supplements in the premium segment for dogs and cats. The purchase price amounts to approximately MSEK 34.8 (MCAD 4.5) and consists of approximately MSEK 27.9 (MCAD 3.6) in cash and an issue of 130,939 shares in Swedencare.
The board of directors for the company has, with the support of the authorization from the annual general meeting on April 25th, 2024, resolved on the issue of 130,939 shares to the sellers of MedVant. The reason for the issue is to make payment to the sellers in accordance with the share purchase agreement. The subscription price in the issue was determined, in accordance with the share purchase agreement, at SEK 53.20 per share, which corresponds to the volume-weighted average price of the company's share on the Nasdaq First North Growth Market during 10 trading days before the date of signing the agreement. The board therefore assesses that the subscription price is made on market terms. The new issue entails a dilution of approximately 0.08 percent based on the total number of shares and votes in the company after the issue.
For more information about the acquired business, please see press release from July 24th, 2024, when the acquisition was made public on the Company homepage www.swedencare.com.
For more information, please contact:
Håkan Lagerberg, CEO Swedencare
Phone: +46 (0)73 517 01 70
Email: hakan.lagerberg@swedencare.se
Jenny Graflind, CFO Swedencare
Phone: +46 (0)73 944 85 54
Email: jenny.graflind@swedencare.se
FNCA is the company’s Certified Adviser
Please visit the Company homepage www.swedencare.com
About Swedencare
Swedencare, a listed company on NASDAQ First North Growth Market, develops, produces and sells premium products in the global and fast-growing market for healthcare products for cats, dogs and horses. The company has an extensive product portfolio with strong brands such as NaturVet®, Innovet, Pet MD®, Rx Vitamins®, nutravet®, and ProDen PlaqueOff®, the original for good oral health. Swedencare’s headquarter is in Malmö, Sweden and the company's products are currently sold in approximately sixty-five countries to veterinarians, pet stores, and online through a distribution network, including subsidiaries in nine countries and an international network of retailers. Swedencare's sales have increased significantly over several years with maintained high profitability.